SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 208.29-0.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (18761)4/7/1998 9:05:00 AM
From: Arthur Radley  Read Replies (1) of 32384
 
They say timing is everything. Would it not be a fantastic event if the following news release had not be offered on February 11, 1998 but instead, issued on April 6, 1998:

STUDY IN ANIMAL MODEL DEMONSTRATES TARGRETIN MORE EFFECTIVE THAN TAMOXIFEN;LIGAND EVALUATES PHASE II CLINICAL TRIALS FOR BREAST CANCER

San Diego, Feb. 11---Targretin(tm) (LGD 1069), a member of an increasingly important new class of drugs called retinoids, caused complete regression in 72 percent of established breast cancer tumors in one of the most commonly used rat models of this disease, according to a study published by scientists from Ligand Pharmaceuticals Inc. in the current issue of Cancer Research.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News